DexCom Profile

USD 2.60  1.86%

Sale by Andrew Balo of 4946 shares of DexCom

DexCom insider trading alert for sale of common stock by Andrew Balo, SVP Regulatory and Clinical, on September 24, 2018. This event was filed by Dexcom Inc with SEC on 2014-03-13. Statement of changes in beneficial ownership - SEC Form 4. Andrew Balo is currently serves as senior vice president - clinical and regulatory affairs of DexCom [view details]   

DexCom Summary

DexCom (DXCM) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 2,290 people. DexCom is listed under Medical Equipment category by Fama And French industry classification.The company currently falls under 'Large-Cap' category with current market capitalization of 12.56 B. DexCom conducts business under Healthcare sector and is part of Diagnostics & Research industry. This company has 88.36 M outstanding shares of which 6.73 M shares are currently shorted by private and institutional investors with about 5.33 trading days to cover. DEXCOM currently holds about 606.1 M in cash with 110.1 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.86.
Check DexCom Probability Of Bankruptcy

Ownership Allocation (%)

DexCom Target Price Odds Analysis

Odds Below 142.1HorizonTargetOdds Above 142.1
50.24%30 days 142.10 49.32%
Based on normal probability distribution, the odds of DexCom to move above current price in 30 days from now is about 49.32% (This DexCom probability density function shows the probability of DexCom Stock to fall within a particular range of prices over 30 days) .

DexCom Top Holders

DexCom Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares7.1 M676.9 M
Fmr LlcCommon Shares7.1 M674.3 M
View DexCom Diagnostics

DexCom Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

DexCom Key Fundamentals

DexCom Against Markets

DexCom Current Ratings

DexCom 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for DexCom are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DexCom operates under Diagnostics Research classification in USA and traded on BATS Exchange. It employs 2290 people. more
Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
DexCom SEC Filings
DexCom SEC Filings
Security & Exchange Commission EDGAR ReportsView All
CEO and President and DirectorKevin SayerView All
Thematic Classification
Currently Active Investing Idea
Medical Equipment
  Medical Equipment
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Diagnostics & Research
InstrumentUSA Stock View All
RegionNorth America
Business Address6340 Sequence Drive
ExchangeBATS Exchange
CIK Number0001093557
IndustryDiagnostics & Research
Phone858 200 0200
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 31, 2018

DexCom Directors

DexCom Corporate Directors

Eric Topol Independent Director
Nicholas Augustinos Independent Director
Mark Foletta Independent Director
Additionally see Investing Opportunities. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.